This roundtable discussion serves to further clinicians' understanding of the safety and efficacy profiles of new colorectal cancer agents, provide insight into how to manage adverse effects, and elucidate how best to incorporate these agents in the appropriate sequence.
In this Key Insights activity, Dr Scott Kopetz and conference chair Axel Grothey discuss the key colorectal cancer-related take-home messages from the Great Debates and Updates in Gastrointestinal Malignancies conference.
A pilot program for Direct Access Colonoscopy Screening (DACS) increased overall screening rates for colorectal cancer by nearly 100% in a selected cohort, according to study results.
Costs associated with maintenance bevacizumab (Avastin, Genentech/Roche) and capecitabine for patients with metastatic colorectal cancer exceeded willingness-to-pay thresholds and were not deemed cost-effective, according to an analysis of randomized trial data.
A recent study presented at the 2018 Gastrointestinal Cancers Symposium identified the difference between right-sided and left-sided tumors in regard to disease-free survival outcomes in patients with late stage, high-risk colorectal cancer.
A liquid biopsy can detect colorectal cancer at an early stage and with accuracy near 90%, according to research scheduled to be presented at the 2018 Gastrointestinal Cancers Symposium (January 18-20, 2018; San Francisco, CA).
Approximately 20% of individuals younger than age 50 who are diagnosed with colorectal cancer carry a germline mutation associated with cancer, despite having no clinical or family history of the disease.
Patients aged 45 years or younger with colorectal cancer may have better treatment options available to them because of more mutations in their tumors than older patients, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).
Patients with rectal cancer who undergo first-line chemotherapy and radiation have lower risk of recurrence and higher rates of survival regardless of whether they choose to have surgery, according to a study published in The Lancet Gastroenterology & Hepatology (published online May 4, 2017: doi:10.1016/S2468-1253(17)30074-2).
Patients with colorectal cancer can decrease their risk of disease-related mortality by 54% if they consume certain types of food, according to a study presented at Digestive Disease Week (May 6-9, 2017; Chicago, IL; abstract 82).